Scott Dunseth Myers net worth and biography

Scott Myers Biography and Net Worth

Scott has worked in the global pharmaceutical and medical technology industries for nearly three decades. He was Chief Executive Officer, President and Director of Viridian Therapeutics, a publicly traded biotechnology company, until November 2023. He was previously Chief Executive Officer and served on the Board of Directors of AMAG Pharmaceuticals, where he led its turnaround and strategic sale to Covis Pharma, S.à.r.l., a pharmaceutical company. Scott served as Chief Executive Officer and Chairman of the Board of Directors of Rainier Therapeutics where he led Rainier’s asset sale of vofatamab to Fusion Pharmaceuticals. Prior to Rainier, Scott served as Chief Executive Officer, President and Director of Cascadian Therapeutics from April 2016 through its acquisition by Seattle Genetics. Scott also serves as Chairperson of the Board of Directors of Convergent Therapeutics. He previously served on the Boards of Directors of Dynavax Technologies Corporation, Harpoon Therapeutics, Selecta Biosciences, Trillium Therapeutics, and Ironshore Pharmaceuticals. Scott holds a B.A. in biology from Northwestern University and an M.B.A. from the Graduate School of Business (Booth) at the University of Chicago. Scott qualifies as an “independent” director in accordance with the listing requirements of Nasdaq.

What is Scott Dunseth Myers' net worth?: The estimated net worth of Scott Dunseth Myers is at least $146.32 thousand as of August 22nd, 2025. Mr. Myers owns 35,004 shares of Zentalis Pharmaceuticals stock worth more than $146,317 as of May 7th. This net worth estimate does not reflect any other investments that Mr. Myers may own. Learn More about Scott Dunseth Myers' net worth.
How do I contact Scott Dunseth Myers?: The corporate mailing address for Mr. Myers and other Zentalis Pharmaceuticals executives is 530 SEVENTH AVENUE SUITE 2201, NEW YORK NY, 10018. Zentalis Pharmaceuticals can also be reached via phone at 212-433-3791 and via email at [email protected]. Learn More on Scott Dunseth Myers' contact information.
Has Scott Dunseth Myers been buying or selling shares of Zentalis Pharmaceuticals?: Scott Dunseth Myers has not been actively trading shares of Zentalis Pharmaceuticals during the last ninety days. Most recently, on Wednesday, April 30th, Scott Dunseth Myers bought 21,000 shares of Zentalis Pharmaceuticals stock. The stock was acquired at an average cost of $1.40 per share, with a total value of $29,400.00. Following the completion of the transaction, the director now directly owns 281,192 shares of the company's stock, valued at $393,668.80. Learn More on Scott Dunseth Myers' trading history.
Who are Zentalis Pharmaceuticals' active insiders?: Zentalis Pharmaceuticals' insider roster includes Kimberly Blackwell (Director), Ingmar Bruns (Chief Medical Officer), Kevin Bunker (COO), Melissa Epperly (CFO), Cam Gallagher (Director), David Johnson (Director), Scott Myers (Director), Alexis Pinto (Insider), Jan Skvarka (Director), Anthony Sun (CEO), and Dimitris Voliotis (SVP). Learn More on Zentalis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Zentalis Pharmaceuticals?: In the last twelve months, Zentalis Pharmaceuticals insiders bought shares 1 times. They purchased a total of 6,459,973 shares worth more than $7,751,967.60. In the last twelve months, insiders at the sold shares 8 times. They sold a total of 7,546,617 shares worth more than $10,088,416.65. The most recent insider tranaction occured on February, 10th when insider Vincent Vultaggio sold 6,894 shares worth more than $16,683.48. Insiders at Zentalis Pharmaceuticals own 1.9% of the company. Learn More about insider trades at Zentalis Pharmaceuticals.
Information on this page was last updated on 2/10/2026.

Scott Dunseth Myers Insider Trading History at Zentalis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/30/2025	Buy	21,000	$1.40	$29,400.00	281,192

Scott Dunseth Myers Buying and Selling Activity at Zentalis Pharmaceuticals

Zentalis Pharmaceuticals Company Overview

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

Today's Range

Now: $4.15

$4.11

$4.18

50 Day Range

MA: $3.25

$2.10

$6.61

2 Week Range

Now: $4.15

$1.13

$6.95

Volume

31,761 shs

Average Volume

1,997,524 shs

Market Capitalization

$295.08 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.99